Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23361379 | 0.85 | GRIN2B (0.48) | GRIN2BCYP1A2CYP3A4CYP2C19SLC6A2 | |
| SCHEMBL23361489 | 0.85 | MAPK14 (0.47) | GRIN2BMAPK14 | |
| SCHEMBL21901796 | 0.79 | GRIN2B (0.44) | GRIN2BCYP1A2CYP3A4CYP2C19SLC6A2 | |
| SCHEMBL23361389 | 0.75 | MRGPRX4 (0.52) | GRIN2BCYP1A2CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL23361385 | 0.72 | GRIN2B (0.48) | GRIN2BCYP1A2CYP3A4CYP2C19SLC6A2 | |
| SCHEMBL23380132 | 0.71 | L3MBTL1 (0.44) | SLC6A2SLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL18921136 | 0.71 | MAPK14 (0.42) | GRIN2BCYP1A2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL23361555 | 0.70 | MAPK14 (0.47) | GRIN2BMAPK14 | |
| SCHEMBL19555362 | 0.69 | S1PR4 (0.48) | SLC6A2SLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL30025714 | 0.69 | S1PR4 (0.48) | SLC6A2SLC6A4KCNH2SLC6A3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-11834409-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11827601-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230150934-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4058430-A1 | HETEROCYCLIC NMDA ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094832-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARAMACEUTICAL COMPANY LIMITED (JP) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | GRIN2B 3/4885CYP1A2 3588/4885CYP3A4 2976/4885 |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | GRIN2B 2/4885CYP1A2 4272/4885CYP3A4 4311/4885 |
| US-11834409-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN2B, GRIN2A | GRIN2B 2/4885CYP1A2 4272/4885CYP3A4 4311/4885 |
| US-20230150934-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | GRIN2B 2/4885CYP1A2 4272/4885CYP3A4 4311/4885 |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | GRIN2B 2/4885CYP1A2 4272/4885CYP3A4 4311/4885 |
| US-11827601-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN2B, GRIN2A | GRIN2B 2/4885CYP1A2 4272/4885CYP3A4 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.